Uwe Staub, PhD
Chief Executive Officer (CEO)
Uwe was appointed as CEO of Epimune on April 01st, 2019. Prior to joining Epimune, Uwe was part of Epigenomics' executive team, and before that, held management positions at Qiagen, Digene and Abbott.
Jeannette Werner, PhD
Vice President Research & Development
Jeannette leads Epimune's in-vitro diagnostic (IVD) test development. Jeannette is a molecular biologist by training and obtained her PhD at the Technical University, Berlin. Before joining Epimune, she was responsible for the R&D activities at Epiontis.
Christoph Sachsenmaier, PhD
Vice President Business Development
Christoph is responsible for Epimune's business development activities. Before joining Epimune, he served as a business development executive at ApoCell, Beckman Coulter Genomics, Epigenomics and ProQinase.
Janika Schulze, M.Sc.
Janika is in charge of Epimune's R&D activities. Janika spent 8 years at Epiontis' R&D department being responsible for assay development. She is finishing her PhD degree at Humbold University, Berlin and spent an extended research stay at Stanford University, CA, USA.
Annett Reichardt, M. Sc.
Quality and Regulatory Affairs Manager
Annett is responsible for Epimune's Quality Management and Regulatory Affairs. Annett brings a wealth of experience from her previous affiliations with Epigenomics, Berlin Cures, Vanguard and BioNTech Diagnostics.
Chief Financial Officer (CFO)
Helge manages Epimune's finances. He gained relevant experiences acting as Controller and CFO at Epiontis. Before that, Helge worked for several companies in the biotech and automotive industry and also co-founded his own IT company.
Epimune is supported by experts from the life science and healthcare industry, high-profile academic researchers and senior advisors with extensive experience in clinical practise, regulatory affairs and finance.